Skip to content
OpenCapital
Get started

MoonLake Immunotherapeutics MLTX EBITDA

Discontinued — last reported Q1 '26

EBITDA at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-$36.39M-45.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.51M-26.0%
Opko Health logo
Opko HealthOPK
-$28.82M+34.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$38.9M+11.8%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$46.24M+73.2%
Eli Lilly logo
Eli LillyLLY
——

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Calculated from MoonLake Immunotherapeutics’s reported figures.

−$70.0Mebit+
$845.0KDepreciation Depletion & Amortization
=-$69.18M

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's EBITDA?
MoonLake Immunotherapeutics (MLTX) reported EBITDA of -$69.18M in Q1 2026.
How has MoonLake Immunotherapeutics's EBITDA changed year-over-year?
MoonLake Immunotherapeutics's EBITDA decreased by 46.9% year-over-year, from -$47.11M to -$69.18M.
What is the long-term trend for MoonLake Immunotherapeutics's EBITDA?
Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's EBITDA has grown at a 67.4% compound annual growth rate (CAGR), from -$51.67M to -$242.22M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.